Numinus Wellness Inc. announced that its founders, Payton Nyquvest and Michael Tan, are returning to their original executive roles as CEO and COO respectively, effective October 1, 2026. This leadership change follows a restructuring phase and aims to guide the company into its next growth phase focused on psychedelic-assisted therapies. Management is actively working to revoke the current cease trade order and has submitted an updated application to the British Columbia Securities Commission. They also plan to list the company's shares on the Canadian Securities Exchange, which would improve shareholder liquidity and support future expansion once approved.
Numinus Wellness leadership changes provide context for health sector trends on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 02, 2026 03:12 WIB: out of 100 priced US health-sector stocks, 13 rose and 86 fell. Notable movers include Danaher Corporation (DHR) at USD 211.68 with a 1-day change of -4.47% and 100% sell order activity, Tilray Brands Inc (TLRY) at USD 3.59 down 4.27% with 77% sell orders, and Abeona Therapeutics Inc (ABEO) at USD 5.03 down 4.19%.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
